Answers are grounded in this paper and cite their sources.
T cells provides an opportunity to elevate response rates of cancer immunotherapies. While there are many challenges left to address, including optimal dose regimen, CD40 agonist profile, combination partners and indications, we are confident that CD40 agonists will play an important role in the challenging task of reprogramming the immune system to fight cancer.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: